Breast Cancer Diagnostic and Drug Technologies: Global Markets

July 09, 2012

Wellesley, Mass.– According to a new technical market research report, BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES: GLOBAL MARKETS (HLC106A) from BCC Research (www.bccresearch.com), the market for predictive diagnostic and drug technologies concerning breast cancer was valued at $21.2 billion in 2011. This figure is projected to reach nearly $24.1 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.5%.

The market for predictive breast cancer diagnostic and drug technologies can be broken down into four categories: breast cancer drugs, quantitative immunofluorescence, genomic analysis, and immunohistochemical (IHC) testing and fluorescent in situ hybridization techniques (FISH).

Breast cancer drugs accounted for $10.2 billion in 2011 and should total $11.2 billion in 2016, a CAGR of 1.9%.

Quantitative immunofluorescence totaled $5.9 billion in 2011 and should reach $6.9 billion in 2016, a CAGR of 3.1%.

Genomic analysis was worth $4.4 billion in 2011 and in 2016 should be worth nearly $5.2 billion, a CAGR of 3.1%.

IHC and FISH accounted for nearly $678 million in 2011 and are expected to be worth nearly $788 million in 2016, a CAGR of 3.1%.

Breast cancer is the most diagnosed cancer in women and is the leading cause of death among women globally. Increased public awareness and improved screening have led to earlier diagnosis, significantly improving survival rates, particularly in younger women. Unfortunately, many early breast cancer growths are not associated with pain or discomfort, and therefore are first detected as abnormalities on mammograms before patients or healthcare providers notice them. The general approach to evaluation of breast cancer involves a clinical examination, which includes imaging (usually mammography and/or ultrasonography) and needle biopsy.

It is estimated that breast cancer will affect one in eight American women during their lifetime.  The World Health Organization estimates that 1.38 million new cases were diagnosed globally in 2008, up from approximately 500,000 cases in 1975. The WHO projects that more than 2.1 million new cancer cases will be diagnosed in 2030. TheUnited Stateshas the highest annual incidence rates of breast cancer in the world. In 2010 alone, an estimated 261,100 women in theUnited Stateswere newly diagnosed with breast cancer. The affordability of treatment is often a concern for women with breast cancer diagnoses. Rising healthcare costs have left a number of patients either uninsured or with less meaningful coverage than they need and deserve.

This report is an exhaustive study on the global breast cancer market, giving crucial statistics and analyses on existing drugs, diagnostic technologies, latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This information may prove crucial for the firms or investors seeking opportunities in the concerned sector.  

To Contact us, click here  

Breast Cancer Diagnostic and Drug Technologies: Global Markets( HLC106A )
Publish Date: Jun 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.